Sort Results:
List of Materials
 |
Changing Landscape of Drug Discovery in Industry SettingsThis lecture entitled “Changing Landscape of Drug Discovery in Industry Settings†introduces the drug discovery and development process to a class focused on a range of topics related to discovery and development of new therapeutic agents... |
Vanderbilt Center for Neuroscience Drug Discovery Vanderbilt University Presenter: P. Jeffrey Conn |
|
CNS Medicinal Chemistry: Introduction and a Case Study – GlyT1This lecture will provide an overview of the drug discovery process with specific attention being paid to the role of medicinal chemistry, and key issues for the CNS disease-focused medicinal chemist (Lipinski’s rules, CNS penetration, transporter... |
Vanderbilt Specialized Chemistry Center (MLPCN) Vanderbilt University Presenter: Craig W. Lindsley |
|
Compliance for Biopharmaceutical LaboratoriesThis primer is intended to introduce FDA and equivalent international requirements. The primer will also give strategies and specific recommendations for regulated laboratories on how to implement the requirements in the most cost effective way. |
Agilent Technologies Presenter: Agilent Technologies |
|
Drug Discovery and the Biopharmaceutical Ecosystem: The Imperative for New R&D Models “The Evolving Role of Academic Drug Discovery”This presentation by Dr. Steven Paul was the keynote address for the "Johns Hopkins Brain Science Institute's Drug Discovery in Academia: The new paradigm in drug discovery" conference.' |
Weill Cornell Medical College of Cornell University Presenter: Steven M. Paul, M.D. |
|
Drug-Like Properties and Druggable TargetsA lecture discussing the concept of drug-like molecular properties, druggable targets, and chemical space. |
Brain Science Institute NeuroTranslational Drug Discovery Program Johns Hopkins University Presenter: Takashi Tsukamoto, Ph.D. |
|
First-In-Man - risk assessmentThe example of TeGenero first-in-man case study was used to explore the usability of systems theoretic accident modeling and processes (STAMP) to create control structure of selected critical points in drug development, approval and... |
ARETE-ZOE, LLC Presenter: Veronika Valdova |
|
Formulation and Route of AdministrationIn order to exert the desired effect in a proof-of-concept animal study, a drug molecule or development candidate first of all needs to be bioavailable and lack of solubility therefore often poses the first barrier to successful translation a... |
Department of Pharmacology UC Davis Presenter: Heike Wulff, Ph.D. |
|
Funding Academic Drug DiscoveryThe NIH supports drug discovery and development for nervous system disorders through a variety of programs. Some provide funding through grants or cooperative agreements to support specific stages of research and development, for particular disease... |
NINDS Office of Translational Research Presenter: Rebecca Farkas, Ph.D. |
 |
Generic Pharmaceutical Drug Solutions GuideAgilent Technologies delivers unique, comprehensive solutions based on industry-leading technology, enabling optimal resource utilization so you can improve productivity and be first to market. |
Agilent Technologies Presenter: Agilent Technologies |
|
Genotoxic Impurities PrimerA synopsis of the regulatory requirements associated with genotoxins, as well as recommendations for their implementation. An overview of relevant analytical instrumentation with useful references to valuable scientific publications. |
Agilent Technologies Presenter: Agilent Technologies |